Steven D. Averbuch - Concepedia

Author

Steven D. Averbuch

The University of Texas MD Anderson Cancer Center

Also Known As

Averbuch, S, S Averbuch, S D Averbuch, S. Averbuch, S. D. Averbuch, S.D. Averbuch, STEVEN D. AVERBUCH, Steven Averbuch, Steven D Averbuch, Steven D. Averbuch

Publications

13.8K

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center National Institutes of Health Memorial Sloan Kettering Cancer Center National Cancer Institute AstraZeneca (United States)

About

Steven D. Averbuch is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	20	1.6K
2	Health Sciences	4	4	264
3	Biochemistry	2	2	67
4	Natural Sciences	1	1	19
5	Social Sciences	1	1	12

Steven D. Averbuch

Publications

13K

Citations

H-Index

Page 1

	Year	Citations
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer Masahiro Fukuoka, Seiji Yano, Giuseppe Giaccone, Journal of Clinical Oncology	2003	2.9K
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer Mark G. Kris, Ronald B. Natale, Roy S. Herbst, JAMA	2003	2.5K
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1 Giuseppe Giaccone, Roy S. Herbst, Christian Manegold, Journal of Clinical Oncology	2004	1.7K
Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2 Roy S. Herbst, Giuseppe Giaccone, Joan H. Schiller, Journal of Clinical Oncology	2004	1.7K
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types José Baselga, Danny Rischin, Malcolm Ranson, Journal of Clinical Oncology	2002	829
Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial Roy S. Herbst, Anne‐Marie Maddox, Mace L. Rothenberg, Journal of Clinical Oncology	2002	577
The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Mark M. Moasser, Andrea Basso, Steven D. Averbuch, PubMed Breast OncologyHer2-driven SignalingTumor BiologyTumor SensitivitySignaling Pathway	2001	508
Malignant Pheochromocytoma: Effective Treatment with a Combination of Cyclophosphamide, Vincristine, and Dacarbazine Steven D. Averbuch, Caryn Steakley, R C Young, Annals of Internal Medicine	1988	423
Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine Hui Huang, Jame Abraham, Elizabeth Hung, Cancer	2008	252
Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition. Seiichi Yano, Kaoru Kondo, Motonori Yamaguchi, PubMed PathologyCell ProliferationDermatologyTumor BiologyOncology	2004	182

Page 1